Posted by Michael Wonder on 06 Aug 2025
Kye Pharmaceuticals announces the approval of Dynavel XR (amphetamine extended release) tablets and oral suspension for the treatment of adults and children with ADHD
5 August 2025 - Kye Pharmaceuticals is pleased to announce the Health Canada approval (notice of compliance) for Dyanavel XR (amphetamine extended release) tablets and oral suspension.
Dyanavel XR is indicated for the treatment of ADHD in adults 18 years of age and over as well as in children aged 6-12 years old.
